Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.8%

3 terminated/withdrawn out of 16 trials

Success Rate

76.9%

-9.6% vs industry average

Late-Stage Pipeline

31%

5 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

7(43.8%)

Phase 3

5(31.3%)

Phase 1

3(18.8%)

N/A

1(6.3%)

16Total

Phase 2(7)

Phase 3(5)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT03948789Phase 3Active Not Recruiting

Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy

Role: lead

NCT02578368Phase 3Completed

Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Role: lead

NCT03673072Phase 3Completed

Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC

Role: lead

NCT04447352Phase 3Recruiting

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Role: lead

NCT02526264Not ApplicableRecruiting

Evaluation of Quality of Life and Period of Hospitalization by Education

Role: lead

NCT00623831Phase 1Completed

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Role: collaborator

NCT01266018Phase 2Terminated

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Role: collaborator

NCT02172976Phase 2Completed

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Role: lead

NCT01248403Phase 3Completed

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

Role: lead

NCT01216644Phase 2Completed

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Role: lead

NCT01569412Phase 1Terminated

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Role: lead

NCT00849615Phase 2Completed

Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Role: lead

NCT01216657Phase 2Terminated

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Role: lead

NCT00737373Phase 2Completed

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Role: lead

NCT01042782Phase 1Completed

Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

Role: lead

NCT01222312Phase 2Completed

Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel

Role: lead

All 16 trials loaded